Cargando…
Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy
Irinotecan treats a range of solid tumors, but its effectiveness is severely limited by gastrointestinal (GI) tract toxicity caused by gut bacterial β-glucuronidase (GUS) enzymes. Targeted bacterial GUS inhibitors have been shown to partially alleviate irinotecan-induced GI tract damage and resultan...
Autores principales: | Bhatt, Aadra P., Pellock, Samuel J., Biernat, Kristen A., Walton, William G., Wallace, Bret D., Creekmore, Benjamin C., Letertre, Marine M., Swann, Jonathan R., Wilson, Ian D., Roques, Jose R., Darr, David B., Bailey, Sean T., Montgomery, Stephanie A., Roach, Jeffrey M., Azcarate-Peril, M. Andrea, Sartor, R. Balfour, Gharaibeh, Raad Z., Bultman, Scott J., Redinbo, Matthew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132129/ https://www.ncbi.nlm.nih.gov/pubmed/32170007 http://dx.doi.org/10.1073/pnas.1918095117 |
Ejemplares similares
-
Characterizing the metabolic effects of the selective inhibition of gut microbial β-glucuronidases in mice
por: Letertre, Marine P. M., et al.
Publicado: (2022) -
Mouse Gut Microbiome-Encoded β-Glucuronidases Identified Using Metagenome Analysis Guided by Protein Structure
por: Creekmore, Benjamin C., et al.
Publicado: (2019) -
Structure, function, and inhibition of drug reactivating human gut microbial β-glucuronidases
por: Biernat, Kristen A., et al.
Publicado: (2019) -
Gut Microbial β-Glucuronidase Inhibition via
Catalytic Cycle Interception
por: Pellock, Samuel J., et al.
Publicado: (2018) -
Microbial β-glucuronidases drive human periodontal disease etiology
por: Lietzan, Adam D., et al.
Publicado: (2023)